Call Directions Website

Glaukos At Glaukos we are focused on pioneering new treatments for chronic eye diseases. Innovation is at the core of everything we do.

Our mission at Glaukos is to truly transform vision by pioneering novel platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders and retinal diseases. ​

​Please note when clicking links in our content you will be led outside of the Glaukos page. The site you opt to connect to does not adhere to our privacy policy. You are solely responsible for your interactions on outside websites. ​
​
Important Safety Information​
https://www.glaukos.com/important-safety-information/ ​

​COMMUNITY GUIDELINES: ​
Glaukos welcomes interactions and will respond to questions, comments and feedback, but responses may be delayed or limited. ​

Posts and comments contain the opinions and views of other users and Glaukos is not responsible for their accuracy or reliability. ​

​Do not post about financial, legal and regulatory issues, unsubstantiated claims about products, profanity, defamatory, offensive, discriminatory or demeaning content, threats, violence, illegal behavior, health or medical advice, false or misleading information, personal health information, or proprietary, confidential or sensitive information. ​

Follow Facebook's posting guidelines and terms of use. ​

By participating, you promise to comply with these guidelines, but we reserve the right to remove any posts that do not comply. Continuous violations may result in removal from the follower list and inability to receive news, comment or message/contact us. ​

Disclaimers: ​
Accounts followed by or following Glaukos social media channels do not indicate endorsement of the account, their products and services or content they publish. ​

Glaukos may provide links or references to other sites as part of its content, but it does not take responsibility for the content from those sites and shall not be liable for damages or injuries arising from it. These links are provided as a convenience only. ​

Glaukos reserves all rights to the channels, including the right to add, remove or modify content, discontinue the account, accept/reject followers and respond to comments. ​

Only Glaukos and its authorized users may represent Glaukos. Any other representation of Glaukos without authorization will result in legal action. ​

​Medical Side Effects/Adverse Events: ​
If you believe you have experienced any medical side effects or reactions from the Glaukos iLink cross-linking procedure or iStent portfolio of products, consult your physician or healthcare professional and report it to Glaukos by calling 1-844-528-3376, Option 1 or by contacting the FDA at 1-800-FDA-1088. ​

​Avoid sharing personal health information on social media channels, but if you do share information about any side effects, Glaukos may contact you for more information. Posts about side effects may be removed from our channels due to legal requirements. ​

Glaukos will not store or use your personal information, but if you report any adverse events or product issues, we need to store and use identifying information about you to submit it to Glaukos and/or regulatory authorities. ​

​Please be aware that Facebook also has access to information shared on our channels, refer to Facebook's Privacy Policy for more details. ​

A new claims registry is poised to give the eye care field something we have never had: data on how glaucoma is treated ...
10/22/2026

A new claims registry is poised to give the eye care field something we have never had: data on how glaucoma is treated in U.S. private practice.

The Newton Registry includes 724,728 encounters across 157,246 patients, 605 providers, and 35 U.S. practices over 18–36 months.

An initial insight from the paper: Only 12.2% of patients in the Newton Registry underwent any glaucoma procedure over 18–36 months, even among providers self-identified as being interested in Interventional Glaucoma.

Read more in Ophthalmology and Therapy: https://rdcu.be/2atQqnzB5F6a

What does it take to bring Epioxa®(riboflavin 5′-phosphate ophthalmic solution) into your practice?Join us for Episode 1...
10/06/2026

What does it take to bring Epioxa®(riboflavin 5′-phosphate ophthalmic solution) into your practice?

Join us for Episode 1: Epioxa Acquisition in the new Getting Started with Epioxa® webinar series. Moderator Matt Jensen, MBA, is joined by Alan Faulkner, MD, PCEO, practice administrator Chris Faulkner, and Scott Honda, Reimbursement Director, Glaukos, for a candid discussion on acquiring Epioxa, buy-and-bill experience, lessons learned, and moving from initial procurement to a successful transition by starting small and scaling smart.

October 15 | 5 PM PT | 7 PM CT | 8 PM ET

Register for the webinar at https://us02web.zoom.us/webinar/register/WN_91Ltp84sTF6AqTSC5wBfqQ #/registration

For important safety information, visit https://www.epioxa.com/hcp/important-safety-information/.

Preserving vision for the years ahead demands a shift in clinical strategy. Through continuous, drop-free therapies, we ...
09/30/2026

Preserving vision for the years ahead demands a shift in clinical strategy. Through continuous, drop-free therapies, we aim to remove the daily treatment burden for older patients.

Join Epioxa for “Advancing Collaborative Care in Keratoconus Intervention,” a lunch symposium on early recognition, time...
09/30/2026

Join Epioxa for “Advancing Collaborative Care in Keratoconus Intervention,” a lunch symposium on early recognition, timely referral, and ongoing vision management in keratoconus care.

Thursday, October 1, 2026 • 12:00–1:00 PM PT
Anaheim Convention Center, Room 252 B

For important safety information, visit https://www.epioxa.com/hcp/important-safety-information/.

Join Glaukos at AAO 2026 in New Orleans for Epioxa booth talks featuring early clinical experience with Epioxa.Hear from...
09/29/2026

Join Glaukos at AAO 2026 in New Orleans for Epioxa booth talks featuring early clinical experience with Epioxa.

Hear from:
• Ken Beckman, MD — Saturday, October 10, 11:00–11:30 AM
• Leyla Saricay, MD, MSc, FEBO — Sunday, October 11, 1:30–2:00 PM

Visit Glaukos Booth #1103 to learn more.

For important safety information, visit https://www.epioxa.com/hcp/important-safety-information/.

Improving the standard of eye care begins with asking the right questions. What other questions do you think could expan...
09/28/2026

Improving the standard of eye care begins with asking the right questions. What other questions do you think could expand the way of treating intraocular diseases?

Preserving vision in older adults means rethinking how we deliver care. When we take the burden of daily adherence off t...
09/25/2026

Preserving vision in older adults means rethinking how we deliver care. When we take the burden of daily adherence off the patient's shoulders, we protect both their sight and their quality of life. Explore the benefits of sustained-release technology: idosetrhcp.com

Fueled by a shared commitment to improving eye health for all, NBA champion Stephen Curry and Glaukos are teaming up to ...
09/25/2026

Fueled by a shared commitment to improving eye health for all, NBA champion Stephen Curry and Glaukos are teaming up to raise awareness for keratoconus (KC), a rare, sight- threatening corneal disease.

Stephen is sharing his own personal journey living with KC to empower others to prioritize proactive eye care and show how early detection is the best defense.

Keep an eye on your vision health and learn more about KC by visiting CouldItBeKC.com

Today, in partnership with NBA champion Stephen Curry, Glaukos Corporation is proud to announce the launch of “Could It ...
09/23/2026

Today, in partnership with NBA champion Stephen Curry, Glaukos Corporation is proud to announce the launch of “Could It Be KC?”, a disease awareness and educational campaign to improve recognition and earlier detection of keratoconus (KC), a rare, sight-threatening corneal disease.

Learn more about the campaign and Glaukos' commitment to improving eye health for all: https://investors.glaukos.com/news/news-details/2026/Glaukos-Partners-with-NBA-Champion-Stephen-Curry-to-Launch-Could-it-be-KC-Campaign-to-Raise-Awareness-of-Keratoconus/default.aspx

Address

1 Glaukos Way
Aliso Viejo, CA
92656

Alerts

Be the first to know and let us send you an email when Glaukos posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share